Publication
Number of items: 8.
10 January 2025
  • Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders : A pharmacovigilance perspective. (2025) S Chiappini, A Guirguis, N Schifano, J Corkery, F Semeraro, A Mosca, G D'Andrea, G D Papanti, D Arillotta, G Floresta, G Martinotti and F Schifano
    • 19 October 2020
  • High lifetime, but low current, prevalence of new psychotropic substances (NPS) use in German drug detoxification treatment young inpatients. (2020) Norbert Scherbaum, Friedrich Seiffert, Fabrizio Schifano, Michael Specka, Udo Bonnet and Stefan Bender
    • 4 January 2016
  • The potential utility of some legal highs in CNS disorders. (2016) Colin Davidson and Fabrizio Schifano
    • December 2012
  • The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine) : A brief review. (2012) John Corkery, E. Durkin, S. Elliott, Fabrizio Schifano and A. Hamid Ghodse
    • 2012
  • 2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol) : A preliminary review. (2012) John Corkery, Fabrizio Schifano, A. Hamid Ghodse, S. Elliott and Ornella Corazza
  • Identifying emerging trends in recreational drug use : outcomes from the Psychonaut Web Mapping Project. (2012) Paolo Deluca, Zoe Davey, Ornella Corazza, Manuela Pasinetti, C. Pezzolesi, Fabrizio Schifano, Lucia Di Furia, Magi Farre, Marta Torrens, Liv Flesland, Arvid Skutle, E. Iversen, Miia Mannonen, A. Majava, Teuvo Peltoniemi, Norbert Scherbaum, Holger Siemann and Peer van der Kreeft
    • 2011
  • Suicide verdicts as opposed to accidental deaths in substance-related fatalities (UK, 2001–2007). (2011) A.E. Vento, M. Pompili, Fabrizio Schifano, John Corkery, M. Innamorati, P. Girardi and H. Ghodse
    • 2006
  • Are placebo-controlled trials still important for obsessive compulsive disorder? (2006) Naomi Fineberg, C. Hawley and T.M. Gale